Induction Chemotherapy Combined With Tislelizumab for Locally Advanced Squamous Cell Carcinoma of the External Auditory Canal

NCT07370337 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Squamous Cell Carcinoma of External Auditory Canal
Locally Advanced Tumor

Interventions

DRUG: Tislelizumab

Sponsor

Eye & ENT Hospital of Fudan University